Scholarlink

<p>The d emographic shift toward an older population is accelerating the prevalence of age-related diseases. Precision geromedicine represents a paradigm shift in targeting the biological processes of ageing to optimise health and healthspan, which likely requires multimodal tailored interventions. PROMETHEUS, as part of the XPRIZE healthspan semi-finalist competition, is an 8-week feasibility and exploratory study including 20 middle-aged-to-older participants who received a multimodal intervention comprising fundamental and augmented interventions. The fundamental interventions include sleep and dietary recommendations; supplementation with whey protein, creatine, and fucoidan; supervised exercise with an exergaming component (dual-task cognitive-physical training); motivational interviewing; and cognitive behavioural therapy. The augmented intervention is further personalised based on predefined gerotypes, reflecting individual ageing patterns beyond chronological age. At baseline, urolithin A, nicotinamide mononucleotide, and/or multivitamin-multimineral were prescribed to participants based on their muscle mass, VO<sub>2</sub>peak, and cognitive performance. At mid-intervention, interventions were adjusted based on individual response, including dose escalation and/or the addition of ergothioneine for inadequate improvement in cognition. Primary outcomes include measures of muscle strength and mass, immune function and cognitive performance, and feasibility indicators such as adherence and trial completion. Secondary outcomes include assessments of other biological, clinical, and digital biomarkers of ageing, as well as qualitative indicators of motivation and personal values. This study is aimed at investigating the recruitment feasibility, safety, adherence, and exploratory outcome trajectories of a multimodal, personalised precision geromedicine intervention protocol based on individual participant’s baseline characteristics and interim responses. These findings will also inform the design of a subsequent 12-month, randomised controlled trial evaluating personalised lifestyle and nutraceutical strategies with the potential to incorporate repurposed pharmacological agents to optimise age-related health outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月3日

查看全文
  • Ajla Hodzic Kuerec,
  • Lihuan Guan,
  • Weilan Wang,
  • Duarte Barros,
  • Wejdan M. Alenezi,
  • Jozo Grgic,
  • Vanessa K. Wazny,
  • Jordi Morwani-Mangnani,
  • Mazzarine Dotou,
  • Dingding Zhang,
  • Tong Chen,
  • Jiaqiu Wang,
  • Jane Yu Ying Ong,
  • Jian Hua Tay,
  • Natasha To-Anan,
  • Christian R. Sotelo,
  • Atikah D. Binti Naseer Khan,
  • Wester Bruggink,
  • Sabarinath V. Nair,
  • Saiful A. Bin Mohamed Sukor,
  • Shivaji Rikka,
  • Renee Chng Yee Sin,
  • Hui Min Chong,
  • Faiz Bin Mohamed Hashim,
  • Sharon N. Binte Shahul Hameed,
  • Anees B. Binte Abdul Hamid,
  • Xin Jin,
  • Carmina Fuster,
  • Yong Chen,
  • Anna Milani,
  • Cuilin Zhang,
  • Paul Macary,
  • Timothy R. Singham,
  • Karishma Sachaphibulkij,
  • Michael Dunn,
  • Lin Yi,
  • Andrea B. Maier

摘要

The d emographic shift toward an older population is accelerating the prevalence of age-related diseases. Precision geromedicine represents a paradigm shift in targeting the biological processes of ageing to optimise health and healthspan, which likely requires multimodal tailored interventions. PROMETHEUS, as part of the XPRIZE healthspan semi-finalist competition, is an 8-week feasibility and exploratory study including 20 middle-aged-to-older participants who received a multimodal intervention comprising fundamental and augmented interventions. The fundamental interventions include sleep and dietary recommendations; supplementation with whey protein, creatine, and fucoidan; supervised exercise with an exergaming component (dual-task cognitive-physical training); motivational interviewing; and cognitive behavioural therapy. The augmented intervention is further personalised based on predefined gerotypes, reflecting individual ageing patterns beyond chronological age. At baseline, urolithin A, nicotinamide mononucleotide, and/or multivitamin-multimineral were prescribed to participants based on their muscle mass, VO2peak, and cognitive performance. At mid-intervention, interventions were adjusted based on individual response, including dose escalation and/or the addition of ergothioneine for inadequate improvement in cognition. Primary outcomes include measures of muscle strength and mass, immune function and cognitive performance, and feasibility indicators such as adherence and trial completion. Secondary outcomes include assessments of other biological, clinical, and digital biomarkers of ageing, as well as qualitative indicators of motivation and personal values. This study is aimed at investigating the recruitment feasibility, safety, adherence, and exploratory outcome trajectories of a multimodal, personalised precision geromedicine intervention protocol based on individual participant’s baseline characteristics and interim responses. These findings will also inform the design of a subsequent 12-month, randomised controlled trial evaluating personalised lifestyle and nutraceutical strategies with the potential to incorporate repurposed pharmacological agents to optimise age-related health outcomes.